In a subsequent retrospective analysis of patients with non-CBF AML, age < 64 years, elevated LDH at presentation, and the presence of a FLT3-ITD mutation were independently associated with increased risk of CNS relapse [5, 16–18]. Here, FLT3 is linked to acute myeloid leukemia.